Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
  • A61K39/29—Hepatitis virus
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/32011—Picornaviridae
  • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/32011—Picornaviridae
  • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
  • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S436/00—Chemistry: analytical and immunological testing
  • Y10S436/811—Test for named disease, body condition or organ function
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10S436/00—Chemistry: analytical and immunological testing
  • Y10S436/82—Hepatitis associated antigens and antibodies

Definitions

• This invention relates to a diagnostic antigen for viral hepatitis and to methods for preparing the same.
• Viral hepatitis also known as acute infectious hepatitis, catarrhal jaundice, or as serum hepatitis, is a disease which results from invasion of the liver by the filterable 1H and SH viruses.
• Virus IH also known as Virus A
• Virus A causes epidemic hepatitis. It is usually found in stools and in the blood of infected individuals and is transmitted to others both by direct contact as well as by contaminated carriers such as food and water or blood, serum and blood plasma as well as by contaminated medical instruments.
• Serum hepatitis caused by Virus SH (also known as Virus B) is clinically similar to that caused by Virus 1H except that, in the opinion of several authors, it is found principally in circulatory fluids, not in stools. characteristically, Virus SH evidence may be found in blood, serum, and plasma of diseased individuals mouths, sometimes years, after the infection recedes from its active state.
• Virus SH is transmitted from one individual to another during blood or plasma transfusion or serum inoculation. Too, it may be passed during skin puncture or venipuncture through instruments contaminated with carrier blood and since transmission in these cases occurs by means of human sera infections, the disease is frequently referred to as homologous serum jaundice or homologous serum hepatitis.
• Virus A and Virus B are merely diiferent types of the same virus species or even that they are identical.
• epidemic hepatitis infectious hepatitis and viral hepatitis are often used interchangeably to denote viral invasion of the liver resulting in a pathologic state. It is in this context that the terms are employed in defining this invention.
• human hepatitis virus can be successfully cultivated in tissue cultures of trypsinized animal kidney, or a permanent cell line cultured from animal kidney, and that the lipoid component of the virus so propagated yields a highly effective diagnostic antigen for viral hepatitis.
• the novel antigen possesses numerous advantages in that it can be employed on a large scale; it is not temperature labile; and is simple to use. (The antigen is an extremely reliable diagnostic tool. If a test individual has active or latent viral hepatitis of either the epidemic or the serum type, a positive reading is readily detectable on the skin of the subject.)
• a particularly outstanding advantage of the novel antigen is its function in differential diagnosis of hepatitis.
• liver biopsy is advocated to make a correct diagnosis. This is particularly the case when responsibility for hepatocellular changes due to viral infiltration may be mistakenly assigned to toxic hepatitis.
• the novel viral hepatitis diagnostic antigen can be used to establish absence of toxic hepatitis due to drugs even though the medication had been administered over a long period of time. This is so because the antigen is protein-specific with respect to the antigen-antibody reaction. (If antibodies are present in the circulating blood, either in the latent or active phase of the disease, administration of-the test antigen evokes a positive reaction, and toxic hepatitis is ruled out.) No reaction will occur in the presence of drug hepatotoxicity since administration of the test antigen should not be expected to produce a reaction.
• a suitable method for propagating hepatitis virus is as follows: Pigs are slaughtered, the kidneys removed under aseptic conditions, rinsed in phosphate-buffer salt solution, Hanks solution (or a similar medium), cut into pieces of about 2 to 3 mm. edge length, and washed three or four times in one of the above-named solutions. A 0.25% buffered trypsin solution, pH value 7.5, is allowed to react on the tissue pieces at 37 C., while stirring. About 20 to 30 ml. trypsin solution are required for approximately 50 grams of kidney fragments. After about 20 minutes the process is interrupted and the cell-containing liquid removed and discarded. The reaction vessel is charged again with the same volume of trypsin solution.
• the process is repeated six times every ten minutes, all further cell suspensions obtained being collected in a vessel cooled with ice water.
• the suspension is centrifuged for minutes at about 1000 r.p.m. (180x gravity).
• the supernatant liquid is removed and the sediment is washed with phosphate-buffer salt solution at 37 C. and centrifuged three more times. Any erythrocytes present are sucked off as far as possible.
• An aliquot of the cell suspension is sedimented at between about 100 to 150 times gravity for about ten minutes and the sediment is added to enough prepared nutrient medium to ensure a cell number of about 100,000 to about 250,000 cells/cc.
• the nutrient medium used may be the Medium 199 according to Morgan, Morton and Parker (Proc. Soc.
• Bovine amnion liquid with 10% calf serum as well as penicillin and streptomycin or other culture liquids may also be used as a nutrient medium.
• cell suspension cultures are prepared in tubes or flasks by apportioning out 2 cc. per tube (1.6 x 16 cm.) or cc. per flask (4.5 x 4.5 x 12 cm.).
• the culture vessels are incubated at 37 C.
• the medium is replaced by fresh culture medium every three to four days. After 7 to 9 days of incubation the serum content is reduced to about 3% and the culture vessels contain a mono-layer of epithelial cells and are ready for inoculation with viral material.
• the inoculation of the tissue culture to be used according to the invention with live hepatitis virus can be effected by using aqueous feces suspensions; blood; blood serum; blood plasma; or suspensions of ground organs from persons infected with virus hepatitis.
• Culture liquids of tissue cultures of the virus are also suitable.
• the nutrient medium is decanted and each tube or flask is inoculated with viral material. After 1 to 4 hours fresh nutrient medium is added, the infectious solution either being left in the culture vessel or removed before the nutrient medium is added.
• the nutrient medium is changed 2 to 3 times each week.
• the culture medium is kept at an approximately neutral pH.
• the inoculated tissue cultures are further incubated at temperatures in the range of 34 to 42 C. until cytopathogenic effect is observed.
• the liquid culture substrates are separated from the tissue culture cells.
• the cells are separated from the walls of the culture vessel by means of 0.25% trypsin solution in phosphatebulfered salt solution at 37 C. with frequent shaking and are exposed to trypsin solution for a further 3 to hours at 37 C. or mechanically ground by means of a cell mill. Any virus still cell-bound will be freed by this measure.
• the cell substrate thus treated is cleansed of the undissolved larger particles by low-speed centrifugation.
• the virus can be centrifuged out from the excess liquid and from the separated nutrient substrated by high speed centrifuging for which in general an operation of 60 to minutes at 26,000 to 30,000 times gravity is suitable.
• tissue cultures prepared either from rabbit or Guinea pig kidney cells as well as from He-La cells represent suitable substrates for propagation of hepatitis virus.
• Elementary bodies are found on electron microscopic examination of the total experimental material having the same shape and size as those which are observable in fecal samples of patients with hepatitis, in inoculated embryonated chicken egg and in inoculated tissue cultures prepared from pig kidney cells.
• the cell culture on which the hepatitis virus is grown is preferably one derived from an animal in which human hepatitis is not known to occur. This preference exists to preclude the possibility of latent hepatitis virus in the cell tissue which is cultured and to avoid the presence of antibodies which would cross react with the hepatitis virus and prevent its growth.
• the pig kidney is the preferred source of the cells for culturing. Still further preferred is the use of a permanent cell line prepared from the primary pig kidney cells The preparation of a permanent cell line from about 30 to 35 passages of subcultures from the primary pig kidney culture provides cells about which there is no need to take into consideration possible latent infections of the pig kidney, and it has been found that the cytopathological effect is observed about three days after inoculation with virus material rather than the ten to thirteen days which are required for the destruction of the primary pig kidney cell culture.
• animal kidney culture is a preferred source of hepatitis virus for preparation of the novel antigens
• the antigen can be prepared with equally satisfactory results from fecal lipid of individuals with clinical signs and symptoms of hepatitis and from chorioallantoic membrane of hens eggs.
• Preparation of fecal suspension of virus Stools obtained from patients in the acute stage of infectious hepatitis are used as the source of virus. Control stools are obtained from central personnel and patients without previous history of infectious or serum hepatitis. All stools are stored at refrigerator temperature for no longer than one to four days. Then a 10% suspension of feces in tap water is prepared by homogenization in sterile centrifuge tubes. The homogenate is then centrifuged at 5000 r.p.m. for about one hour. The supernate is separated out and treated with penicillin 400 ,u/ml. and streptomycin u/ml.
• the supernate is then allowed to stand at room temperature for about four hours after which sterility controls are made in Standard-I Bouliion, and incubated at 37 C. for five days.
• the antibiotic supernate is stored in a cool room at 4 C. until further use.
• the fecal suspension (supra) is transferred to the allantoic cavity of the developing chick embryo using 0.2 ml. inoculurn per egg.
• the eggs are incubated at 35 C.- 36 C. for five days, then candled and the embryos still alive are chilled overnight in the cold room at 4 C.
• the chorioallantoic membranes are harvested, pooled and emulsified with tap water, ml. water to each chorioallantoic membrane.
• Control series are initiated either by allantoic cavity injection of normal fecal suspension or no injection into the chorioallantoic membrane. In all other respects the control eggs are handled like the infectious hepatitis series.
• a skin test antigen is prepared in such a way that the virus is inactivated by chemical means, preferably by contact with formalin at a concentration of about 1:2,000 to about 126,000, preferably about 124,000. It is desirable to allow the formaldehyde to remain in contact, preferably at a slightly elevated temperature, e.g., 34 C. to about 41 C., for about 7 to days. Cell residues are separated by centrifugation under sterile conditions.
• a most important feature of our invention resides in the isolation of the antigenic component from the cultured virus. (We have found that the antigen is obtainable from the lipoid fraction of the live virus.) Accordingly, to accomplish the isolation of the antigen successfully, one may employ an organic solvent which will dissolve the desired component without destroying its antigenic power. We have found that solvents most suitable for this purpose are ethyl ether and chloroform.
• the virus particles themselves do not pass into the organic solution layer, together with the infectious nucleoproteins.
• the obtained antigen components therefore are not infectious.
• a suitable dispersing agent such as Twecn80, may be added to ensure uniform distribution of the antigen throughout the liquid phase.
• suspensions are heated for one hour in a water bath at a temperature between 55 C. and 85 C. preferably at a temperature of 60 C.
• Application of the novel antigenic preparation may be cutaneous (topical), on the breast or the upper arm, or intracutaneous (by injection), in the upper arm, the latter in a volume of about 0.1 to about 0.2 cc. About twenty minutes after injection a slight reddening of the skin area is observed which is non-specific and soon subsides. The actual determination of the nature of the response, i.e., negative or positive, is made after twelve to forty-eight hours have elapsed. During that period, at the injection area, there develops a red papula or swelling accompanied by generalized reddening and, occasionally, cockade phenomena. The reaction may last up to about 8 days.
• the antigen of this invention is useful as a diagnostic for hepatitis in homologous and heterologous individuals with chemical signs and symptoms of viral hepatitis.
• the antigen gives a positive reaction when tested against homologous individuals if the virus is present in the starting material.
• the antigens When the fecal skin test antigens are tested on heterologous individuals, in many cases the antigens elicit positive reactions giving just about the same pattern of reaction Whenever tested. There appear to be several strains of hepatitis virus, and it is possible that some individuals harbor more than one strain. For example, it has been observed that two or more heterologous antigens can elicit positive results in one individual, whereas the same antigens are only partially positive in others. This is so because each antibody is specific for an individual antigen and is not capable of reacting with antigens which do not contain common reactive chemical groupings.
• EXAMPLE I Pig kidney tissue culture A kidney is removed from a pig weighing approximately 40 kg. under sterile conditions. The kidney is placed in phosphate-buffered saline solution (PPS) containing 200 I.U. of penicillin and gamma of strepto mycin. The solution is kept at a temperature of 37 C.
• PPS phosphate-buffered saline solution
• a portion of the trypsin solution is decanted and dis carded.
• Fresh trypsin solution is added to the flask to make the volume back up to 25 ml.
• the trypsin solution is decanted into a flask and replaced with fresh trypsin solution.
• the collected fractions are kept in an ice bath.
• the trypsin solution is centrifuged for ten minutes at 1000 rpm. times gravity) to sediment the cells.
• the supernatant is decanted and the cells are washed three times with PPS at 37 C. Any erythrocytes present on the sedimented cells are aspirated off.
• the cells are added to sufiicient tissue culture medium to provide a density 1.25 X10 cells/ml. Fifteen milliliter portions of this cell suspension are added to square flasks having the dimensions 4.5 x 4.5 x 12 cm. To suspend the cells a culture medium of the following composition is used:
• Vfater (deionized) 800 Medium 199 (10X concentrated) 100 2.8% sodium bicarbonate solution 50 1% streptomycin solution 11.3 1.33% penicillin solution 11.3 Calf serum 11.3
• Phenol red is added to the flasks as an indicator.
• the flasks are incubated at 37 C. for five days.
• the culture medium is decanted and replaced with fresh culture me- 7 dium and the flasks are again incubated at 37 C.
• the culture medium is again decanted and replaced with fresh medium and the flasks are again incubated at 37 C. for three days.
• the culture medium is again decanted and a mono-layer of epithelial cells is observed in the flasks.
• EXAMPLE 11 Permanent pig kidney cell line Flasks with nine day old primary pig kidney cultures obtained by the procedure of Example I are washed with calciumand magnesium-free Moscana solution at 37 C.
• the Moscana solution is prepared as follows:
• the Moscana solution is sterilized by filtration through a Seitz filter.
• the culture in each starting flask is divided into three flasks for the growth of the subcultures.
• the culture medium has the following composition:
• EXAMPLE III Virus growth on pig kidney cells
• a flask of primary pig kidney cells prepared according to Example I is inoculated with 2 ml. of inoculum, which is prepared as follows: 3 loops 9 3 mm.) of fecesof a patient suffering from virus hepatitis are stirred in 10 ml. of tap water.
• the suspension is centrifuged for 20 minutes at 2000 times gravity to free it of coarse particles and is filtered through a Schott frit filter No. G5.
• 13.0 ml. of fresh culture medium is added to the flask.
• the serum content of the medium is 3%.
• the flask is incubated at 37 C.
• the medium is replaced with fresh medium three times each week.
• the medium is maintained at approximately neutral pH.
• the cells are observed for cytopathogenic effect.
• the nutrient substrate is separated from the tissue cells and the tissue cells are digested with trypsin solution at 37 C. for 20 hours.
• the suspension is centrifuged at 2000 times gravity for 20 min utes.
• the supernate is separated and centrifuged at 27,000 times gravity.
• the sediment from this centrifugation is suspended in sterile water and is examined for the presence of hepatitis virus by means of an electron microscope.
• EXAMPLE IV Virus growth on pig kidney cells from permanent cell line
• a flask of pig kidney cells prepared according to Example II inoculated with 2 ml. of inoculum pooled hepatitis serum prepared from the sera of four patients suffering from virus hepatitis. After being in contact with the cell culture for two hours at 37 C., 13.0 ml. of fresh culture medium containing 3% calf serum is added to the flask. The flask is incubated at 37 C. in a stationary position. Cytopathogenic effect is observed after ten days. The procedure is repeated for fifteen passages, and cytopathogenic effect is finally observed after three days. The nutrient medium and tissue culture cells are worked up as in Example 111.
• EXAMPLE V Hela cell tissue culture Sixteen tissue culture tubes are seeded, each with 2 ml. of a cell suspension harvested from an Earle-T-Elask. The tissue culture tubes are incubated at 37 C.
• the nutrient medium has the following composition: 65% Hanks solution, 10% medium 199, 10% lactalbuminyeast-solution, 10% calf serum, 5% horse serum, 0.002% phenol red and penicillin and streptomycin as indicated in previous examples.
• the lactalbumin-yeast solution contains 5 parts by weight lactalbumin hydrolysate and 1 part by weight yeastolate Difco, dissolved in 1,000 parts by volume of a phosphate-buffered saline. Nutrient media are charged every two or three days.
• the inoculum is the same as that used in Example 111.
• the tissue cultures are inoculated after 2 days incubation.
• the old nutrient media are removed and 8 tubes each with hepatitis pool.
• the volume of the inoculum is 0.4 cc. each.
• the inoculated tissue culture tubes are incubated for 2 hours at 37 C. after which time the inoculum is pipetted off and 2 ml. of first nutrient medium are filled into each of the tubes.
• tissue cultures inoculated with control pool or with hepatitis pool respectively are processed according to the time scale shown below:
• EXAMPLE VII Production of antigen from tissue culture Tissue culture suspension prepared as described above (Examples III and IV) are inactivated with formaldehyde at a final dilution of 124000. The procedure is performed at 37 C. over a period of twelve days. After inactivation the suspension is deformalized by dialysis against distilled water at 4 C. for three days, the water being changed once daily. At the end of three days the preparation is tested for bacterial contamination. The deformalized preparation is the skin test antigen.
• EXAMPLE VIII Production of antigen from fecal extract Using sterile test tubes, one loopful of the lipid extract prepared as described in Example VI is dissolved in 1 ml. of ethyl ether. The solvent containing the lipid complex is then evaporated under reduced pressure. The remaining lipid complex is resuspended in 3.5 ml. of physiological saline. The test tube is well shaken to obtain homogeneity, after which inactivation is accomplished by raising and maintaining the temperature to 60 C. for a period of one hour. The resulting antigen preparation is stored in a refrigerator.
• EXAMPLE 1X Production of antigen from choriollantois An equal volume of glycerine is added to the emulsified suspension of choriollantoic membrane (supra), with final addition of 0.25% phenol. The mixture is placed in a water bath and kept at boiling temperature for eight hours. After cooling, 3.5 ml. is transferred to a separatory funnel and 7.0 ml. chloroform is added. The mixture is shaken gently for five minutes and then allowed to stand. The chloroform phase is drawn OE and saved. The procedure is repeated, adding 7.0 ml. chloroform to the chorioallantoic-glycerine preparation to complete extraction of the lipid complex from the virus containing material.
• the two chloroform phases are pooled and evaporated under reduced pressure.
• the remaining lipid complex is resuspended in 3.5 ml. sterile physiological saline and shaken to homogenicity.
• the suspension is inactivated at 60 C. for about one hour.
• the resulting antigen preparation is stored at 4 C.
• a preparation useful in the diagnosis of viral hepatitis comprising a physiological suspension of antigenic components of human hepatitis virus, said antigenic components being the residue obtained by extracting human hepatitis virus containing pig kidney cells with an organic solvent selected from the group consisting of ethyl ether and chloroform separating the solvent from the cellulor material and subsequently evaporating the organic solvent.
• a method of diagnosing viral hepatitis in humans which comprises intracutaneously injecting a composition comprising a physiological suspension of an antigenic component of human hepatitis virus, said antigenic component being the residue obtained by extracting human hepatitis virus containing pig kidney cells with an organic solvent selected from the group consisting of ethyl ether and chloroform separating the solvent from the cellular material and subsequently evaporating the organic solvent, and observing the response thereto, a positive response being indicated by swelling and reddening at the site of injection after about 12 to 48 hours.
• a method of propagating human hepatitis virus which comprises inoculating pig kidney tissue cells with human hepatitis virus, providing the inoculated cells with nutrient fluid capable of supporting growth of the pig kidney tissue cells, and incubating the inoculated culture at a temperature of about 34-42 C. until cytopathogenic effect is observed.
• a method of obtaining a diagnostic antigen for viral hepatitis which comprises extracting the antigenic components of human hepatitis virus with an organic solvent selected from the group consisting of ethyl ether and chloroform separating the solvent from the human hepatitis virus, evaporating the solvent and suspending the resulting antigenic residue in a physiological fluid.
• a method of obtaining a diagnostic antigen for viral hepatitis which comprises extracting the antigenic components of human hepatitis virus with an organic solvent selected from the group consisting of ethyl ether and chloroform separating the solvent from the human hepatitis virus, evaporating the solvent, suspending the resulting antigenic residue in a physiological fluid and heating the suspension for about one hour at a temperature of about 5585 C.
• a method of obtaining a diagnostic antigen for viral hepatitis which comprises inoculating pig kidney cells with human hepatitis virus, providing the inoculated cells with nutrient fluid capable of supporting growth of the pig kidney cells, incubating the inoculated culture at a temperature of about 34 to 42 C. to propagate the virus therein, separating and inactivating the virus without destroying its antigenicity, and recovering the inactivated, antigenic virus.
• a method of obtaining a diagnostic antigen for viral hepatitis which comprises inoculating pig kidney cells with nutrient fluid capable of supporting growth of pig kidney cells, incubating the inoculated culture at a temperature of about 3442 C., until cytopathogenic effect is observed, separating and treating the virus by contact with formaldehyde at a concentration of about 122000 to 126000 at a temperature of about 3441 C., for about 7 to 15 days, and deformalizing and recovering the treated virus.
• a method of obtaining a diagnostic antigen for viral hepatitis which comprises inoculating pig kidney cells with human hepatitis virus, providing the inoculated cells with nutrient fluid capable of supporting growth of the pig kidney cells, incubating the inoculated culture at a temperature of about 3442 C. until cytopathogenic effect is observed, separating and treating the virus by contact with formaldehyde at a concentration of about 1:2000 to 1:6000 at a temperature of about 3442 C. for about 7 to 15 days, and separating the treated virus from low molecular weight components and formaldehyde by dialysis against distilled Water.
• a method of obtaining a diagnostic antigen for viral hepatitis which comprises extracting the antigenic components of human hepatitis virus from a human hepatitis virus infected fecal suspension with an organic solvent selected from the group consisting of ethyl ether and chloroform separating the solvent from said fecal suspension, evaporating the solvent and suspending the resulting antigenic residue in a physiological fluid.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Microbiology (AREA)
• Virology (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Molecular Biology (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Biotechnology (AREA)
• Urology & Nephrology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• Communicable Diseases (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Animal Behavior & Ethology (AREA)
• Biomedical Technology (AREA)
• Pharmacology & Pharmacy (AREA)
• Hematology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Genetics & Genomics (AREA)
• Cell Biology (AREA)
• Biophysics (AREA)
• Pathology (AREA)
• General Physics & Mathematics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• Food Science & Technology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (7)

Applications Claiming Priority (1)

Publications (1)

Family

ID=23836273

Family Applications (1)

Country Status (4)

Cited By (3)

Citations (5)

• 1965
  • 1965-06-08 US US462391A patent/US3313706A/en not_active Expired - Lifetime
• 1966
  • 1966-02-23 FR FR50718A patent/FR5333M/fr not_active Expired
  • 1966-05-04 SE SE06107/66A patent/SE347658B/xx unknown
  • 1966-05-25 CH CH752866A patent/CH479288A/de not_active IP Right Cessation

Patent Citations (5)

Also Published As

Similar Documents